Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · (multiple, generic dominant) (1) · Many generics/OTC (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)

2C-x series (1) · Analgesic (2) · Opioid (2) · Phenethylamine (1) · Prodrug (1) · Psychedelic (1) · [[:Category:B-vitamins|B-vitamin]] (1) · [[:Category:Vitamins|Vitamin]] (1)

5-HT2A partial agonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-0000124C-QINU`"' The 400 mg/d dose for migraine prophylaxis is supported by randomized trials (Schoenen 1998) and remains a low-risk evidence-based supplement option. Characteristic bright-yellow urine fluorescence with high-dose oral supplementation. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000124D-QINU`"', '"`UNIQ--vote-0000124E-QINU`"', '"`UNIQ--vote-0000124F-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · Migraine prophylaxis: 400 mg PO daily; deficiency replacement 5-30 mg/d (1)

None (2) · 25, 50, 100, 250, 400 mg tablets; OTC (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · No strict ceiling for water-soluble vitamin; UL not set (1)

None (1) · insufflated (1) · IV (rare) (1) · Oral (2) · PO (only formulation marketed in the US). (1) · PR (1)

None (1) · 30–60 min (PO) (1) · 45-75 min (oral) (1) · Migraine effect after 1-3 months of daily use (1)

None (1) · 4-8 h (1) · 4–6 hours (1) · N/A (1)

None (1) · 2.5–3 hours (1) · Not well characterized (1) · ~1-2 hours plasma (riboflavin itself); FAD/FMN tissue cofactors are continuous (1)

None (1) · Not well characterized (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~50-60% (oral; food enhances) (1)

None (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Not established (1) · Safe at replacement and supplement doses.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (1) · OTC in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)